<DOC>
	<DOCNO>NCT00050986</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose new drug ZARNESTRA ( R115777 ) temozolomide give patient brain tumor ( glioblastoma multiforme , GBM ) . The second goal learn drug give combination shrink slow growth brain tumor . The safety treatment also study .</brief_summary>
	<brief_title>Phase I/II Evaluation Temozolomide ZARNESTRA ( R115777 ) Recurrent Progressive Glioblastoma Multiforme</brief_title>
	<detailed_description>Temozolomide work kill cancer cell . R115777 new drug may slow growth cancer cell . Used combination , two drug may control growth brain tumor . Before treatment start , patient complete exam , include measurement height weight . Blood test ( less 2 tablespoon blood ) perform . A MRI scan do . Women able child must negative blood pregnancy test . Temozolomide R115777 take mouth . Participants study take temozolomide day 7 day every week ( Days 1-7 15-21 ) . This repeat every 28 day ( 1 course ) . Patients must eat 1 hour take drug ; drinking water allow . All treatment may give outpatient basis . During alternate week ( Days 8-14 22-28 ) , participant take R115777 tablet mouth morning evening food . At begin study , group 3 participant take increase dos R115777 temozolomide high safe dose drug , give combination , find . Participants enter study high safe dose find receive dosage . If tumor grow serious side effect occur , participant may keep take temozolomide R115777 2 year . If physician think advisable , treatment may continue R115777 alone time . In case , routine blood test count , liver kidney function ( le 2 tablespoon ) repeat every 4 week MRI scan , physical , neurological exam do every 8 week . Participants may receive treatment cancer ( include surgery ) take part study . Participants come clinic complete physical neurological exam blood test ( less 2 tablespoon blood ) course . Blood test repeat week first 2 course treatment Days 14 28 later course . A MRI scan do odd-numbered ( 3 , 5 , 7 , etc . ) course treatment time clinically indicate . At end study , participant another complete physical exam . Blood test ( less 2 tablespoon blood ) perform . A MRI scan do . This investigational study . Temozolomide approve FDA treatment brain tumor commercially available . R115777 approve research use treatment brain tumor . The use two drug together experimental .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>1 . Patients histologically prove supratentorial glioblastoma multiforme ( GBM ) . 2 . Patients must show unequivocal evidence tumor recurrence progression MRI scan radiation therapy . The scan do prior study entry document progression review primary investigator document tumor volume change provide gross assessment growth rate . 3 . Patients may : ) prior chemotherapy , b ) 1 prior adjuvant chemotherapy , c ) 1 prior adjuvant chemotherapy follow 1 regimen recurrent disease , ) 1 2 prior chemotherapy regimens recurrent progressive tumor . 4 . All patient must sign informed consent indicate aware investigational nature study keep policy hospital . 5 . Patients must show unequivocal evidence tumor progression MRI CT scan . A scan performed within 14 day prior registration steroid dose stable least 5 day . If steroid dose increase date image registration new baseline MR/CT require . The type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement . 6 . Pts recent resection recurrent progressive tumor eligible follow condition apply : Pt recover effect surgery ; Residual disease resection recurrent tumor mandate eligibility . To assess extent residual disease postoperatively , CT/MRI do later 96 hour postoperatively least 4 week postoperatively , within 14 day registration . If steroid dose increase day image registration , new baseline scan require stable steroid 5 day . 7 . Patients must Karnofsky performance status &gt; /= 60 8 . Patients must recover toxic effect prior therapy : 4 week prior cytotoxic therapy and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Any question relate definition noncytotoxic agent direct Study Chair . 9 . Patients must adequate bone marrow function ( ANC &gt; /= 1,500/mm ( 3 ) platelet count &gt; /= 100,000/mm ( 3 ) ) , adequate liver function ( SGPT SGOT &lt; /= 2.5 time normal , bilirubin &lt; /= 2 mg % ) , adequate renal function ( BUN creatinine &lt; 1.5 time institutional normal ) prior start therapy . 10 . ZARNESTRA may interfere coumadin dose patient take combination require frequent monitoring PT , PTT INR . 11 . Patient risk factor HIV serologically negative . 1 . Patients must take primidone , carbamazepine , phenobarbital phenytoin anticonvulsant . Patients change anticonvulsant others allow must drug list least 1 week . 2 . Patients must take cimetidine , erythromycin azole antifungal , paclitaxel , tacrolimus cyclosporine . 3 . Patients must uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure , myocardial infarction within previous six month , serious uncontrolled cardiac arrhythmia . 4 . Because concern potentially harmful interaction ZARNESTRA medication take patient HIV positive AIDS related disease , patient HIV positive eligible entry study . Only patient suspect HIV test positive , ineligible . 5 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) ineligible unless complete remission therapy disease minimum 3 year . 6 . Patients must : ) active infection b ) disease obscure toxicity dangerously alter drug metabolism c ) serious intercurrent medical illness . ) prior recurrence either Temozolomide farnesyl transferase inhibitor . 7 . Patients must pregnant must practice adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Brain Neoplasms</keyword>
	<keyword>CNS Diseases</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>R115777</keyword>
	<keyword>Zarnestra</keyword>
</DOC>